Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H18N2O5 |
Molecular Weight | 258.271 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CC(=O)NO)C(=O)[C@@H]1CCCC[C@@H]1C(O)=O
InChI
InChIKey=QKIVRALZQSUWHH-SFYZADRCSA-N
InChI=1S/C11H18N2O5/c1-13(6-9(14)12-18)10(15)7-4-2-3-5-8(7)11(16)17/h7-8,18H,2-6H2,1H3,(H,12,14)(H,16,17)/t7-,8+/m1/s1
Molecular Formula | C11H18N2O5 |
Molecular Weight | 258.271 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Idrapril is an inhibitor of the angiotensin-converting enzyme the last is responsible for recurrent myocardial infarction in patients with left ventricular dysfunction. Idrapril participated in phase II clinical trials in essential hypertensive patients, where was shown that the drug was well tolerated. In addition, it was involved in preclinical studies as a potential drug to treat heart failure and postmyocardial infarction. However, the development of the drug was discontinued.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacology of idrapril: a new class of angiotensin converting enzyme inhibitors. | 1992 Jul |
|
Oral pharmacokinetics and pharmacodynamics of idrapril calcium, the prototype of a new class of angiotensin converting enzyme inhibitors, in humans. | 1993 Dec |
|
Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans. | 1993 Sep-Oct |
|
Angiotensin-converting enzyme inhibition by hydroxamic zinc-binding idrapril in humans. | 1994 Aug |
|
Alteration of cytochrome P-450 isozymes by captopril and idrapril in hepatic and renal microsomes of normotensive and spontaneously hypertensive rats. | 1997 Jul |
Sample Use Guides
in 8 healthy men: Increasing doses of 1, 5, and 25 mg idrapril as well as placebo or 5 mg captopril were administered intravenously (i.v.) at 1-week intervals.
oral: healthy volunteers after multiple dosing for 5 days at the doses of 100, 200 and 400 mg twice daily.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:18:52 GMT 2023
by
admin
on
Fri Dec 15 17:18:52 GMT 2023
|
Record UNII |
176P5C4QU8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C247
Created by
admin on Fri Dec 15 17:18:52 GMT 2023 , Edited by admin on Fri Dec 15 17:18:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6892
Created by
admin on Fri Dec 15 17:18:52 GMT 2023 , Edited by admin on Fri Dec 15 17:18:52 GMT 2023
|
PRIMARY | |||
|
176P5C4QU8
Created by
admin on Fri Dec 15 17:18:52 GMT 2023 , Edited by admin on Fri Dec 15 17:18:52 GMT 2023
|
PRIMARY | |||
|
DTXSID60155565
Created by
admin on Fri Dec 15 17:18:52 GMT 2023 , Edited by admin on Fri Dec 15 17:18:52 GMT 2023
|
PRIMARY | |||
|
C076966
Created by
admin on Fri Dec 15 17:18:52 GMT 2023 , Edited by admin on Fri Dec 15 17:18:52 GMT 2023
|
PRIMARY | |||
|
C83780
Created by
admin on Fri Dec 15 17:18:52 GMT 2023 , Edited by admin on Fri Dec 15 17:18:52 GMT 2023
|
PRIMARY | |||
|
65960
Created by
admin on Fri Dec 15 17:18:52 GMT 2023 , Edited by admin on Fri Dec 15 17:18:52 GMT 2023
|
PRIMARY | |||
|
SUB08120MIG
Created by
admin on Fri Dec 15 17:18:52 GMT 2023 , Edited by admin on Fri Dec 15 17:18:52 GMT 2023
|
PRIMARY | |||
|
127420-24-0
Created by
admin on Fri Dec 15 17:18:52 GMT 2023 , Edited by admin on Fri Dec 15 17:18:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104330
Created by
admin on Fri Dec 15 17:18:52 GMT 2023 , Edited by admin on Fri Dec 15 17:18:52 GMT 2023
|
PRIMARY | |||
|
100000083698
Created by
admin on Fri Dec 15 17:18:52 GMT 2023 , Edited by admin on Fri Dec 15 17:18:52 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |